Amylin Pharmaceuticals, Inc and Takeda Pharmaceutical Company Limited have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in phase-2 development for treatment of obesity. The agreement also includes additional compounds from both companies' obesity research programmes. Amylin will receive a one-time up-front payment of US$ 75 million from Takeda and, over the term of the agreement and in relation to the compounds under the agreement, is eligible to receive additional payments upon achieving certain development, commercialization and sales-based milestones that could exceed US$ 1 billion. The agreement also provides for future tiered, double-digit royalty payments to Amylin based on global product sales.

Under the terms of the agreement, Amylin will be responsible for executing development activities for potential products through phase-2 with the aim of regulatory approval in the US. Takeda will lead development activities beyond phase-2 in the US, and all development activities outside the US. In most instances, Amylin will be responsible for 20 per cent of development costs associated with obtaining approval for products in the US and Takeda will be responsible for 80 per cent of such US development costs. Takeda will be responsible for 100% of development costs associated with obtaining approval for products outside the US.

Takeda will lead product commercialization, both in the US and outside the US, and will be responsible for 100 per cent of commercialization costs. Amylin will have the option to co-commercialize the first two approved products in the US and any follow-on products containing the identical active ingredients.


"Takeda is excited to realize this partnership with Amylin focused on the treatment of obesity and related indications. By leveraging Takeda's global development and commercial infrastructure we look forward to maximizing the significant potential of the products under this agreement," said Yasuchika Hasegawa, president & chief executive officer, Takeda Pharmaceutical Company Limited. "Both Amylin and Takeda have extensive experience in the diabetes and metabolic disease area, and this collaboration should allow us to more quickly bring promising new treatments to patients in need."


"This collaboration will leverage Amylin's experience and expertise with peptide and protein science and Takeda's worldwide development and commercial expertise," said Daniel M Bradbury, president and chief executive officer, Amylin Pharmaceuticals. "Amylin recognizes the enormous potential of this collaboration to advance more options in obesity treatment more quickly than either company could do alone. Amylin and Takeda are excited about working together to address the significant unmet need for the millions of patients who need better solutions to manage obesity."
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals.